April 21 Inotek Pharmaceuticals Corporation * Announces issue of Stage 1 information for trabodenoson in
sizable grown volunteers in the Daybook of Optic Pharmacology
and Therapeutics
* Trabodenoson secure, swell tolerated and resulted in no
dose-related optic or systemic position effects
Reference textbook for Eikon:
Advance companionship reporting:
(Bengaluru Newsroom: +1-646-223-8780)
Wednesday, April 20, 2016
BRIEF-Inotek Pharmaceuticals announces publication of Phase 1 data for trabodenoson
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment